^
Association details:
| Biomarker: | ABCG2 expression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Sutent (sunitinib) (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) + elacridar (GF120918) (P-glycoprotein inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
418 / 13 - Elacridar potentiates sunitinib efficacy in colorectal cancer models
Published date:
03/15/2023
Excerpt:
Models that expressed ABCB1 or ABCG2 were pre-incubated with a non-toxic dose of elacridar, a potent transporter inhibitor....ABCB1 and ABCG2 expression was observed in all CRC models except for HT29 cells, which did not express ABCB1. Pre-incubation with elacridar significantly improved sunitinib efficacy in CRC cells. The IC50 decreased from 2.15 µM to 1.17 µM (p = 0.04), from 1.32 µM to 0.44 µM (p = 0.03), and from 4.94 µM to 3.43 µM (p = 0.03) for HT29, COLO320 and CACO2 cells respectively.
